A Phase 1b/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DISC-0974 in Participants With Myelofibrosis and Anemia
Latest Information Update: 22 Jul 2024
At a glance
- Drugs DISC 0974 (Primary)
- Indications Anaemia; Myelofibrosis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Disc Medicine
- 14 Jun 2024 According to a Disc Medicine Media Release, management will host a call to review the presented data on Friday, June 14th at 8:00 am ET.
- 14 Jun 2024 According to a Disc Medicine Media Release, data from this study presented at the European Hematology Association (EHA) 2024 Congress.
- 14 Jun 2024 Results presented in a Disc Medicine Media Release.